• For Institutions

  • Download
  • Help
  • About

longbridgelongbridge
longbridgelongbridge
Products
Pricing
Markets
Global Markets
Stock Screener
Information
Insights
News
Live
Academy
Affiliate Program
Promotions
PortAI
EN
English
简体中文
繁體中文
繁體中文(廣東話)Posts & comments will be shown in Cantonese
Search...
Quote ListQuote List
Overview
News
Financials
© 2025 Longbridge|Disclaimer

Event Tracking

Nov25
Inhibrx Biosciences Reports Q3 2025 Earnings and ozekibart Clinical Trial Progress
04:12
Nov15
Inhibrx Biosciences released FY2025 9 Months Earnings on November 14, 2025 (EST), with actual revenue of USD 1.3 M and EPS of USD -6.9325
04:00
Inhibrx Biosciences released FY2025 Q3 earnings on November 14 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -2.28 (forecast USD -1.72)
04:00
Nov14
Inhibrx Biosciences Inc. Reports Q3 2025 Loss and Publishes ozekibart Trial Results
11:00
Nov4
Inhibrx Biosciences Inc. Announces Positive Phase 2 Results for Ozekibart (INBRX-109) in Chondrosarcoma
21:02
Oct30
Inhibrx Reports Positive Phase 2 Results for Ozekibart in Advanced Chondrosarcoma
22:44

Schedules & Filings

Schedules
Filings
Nov14
Earning Release(EST)

FY2025 Q3 Earning Release (USD) Net Income -35.26 M, EPS -2.28

Aug13
Earning Release(EST)

FY2025 Q2 Earning Release (USD) Revenue 1.3 M, Net Income -28.65 M, EPS -1.8524

May14
Earning Release(EST)

FY2025 Q1 Earning Release (USD) Net Income -43.31 M, EPS -2.8

View More

Stock List

Top Gainers
Top Decliners
China Concepts
Symbol
Price
%Chg
Change
MSOX
7.940
+107.85%
+4.120
YCBD
1.200
+90.17%
+0.569
THH
15.520
+57.72%
+5.680
WEED
25.325
+55.65%
+9.055
NCI
1.920
+54.84%
+0.680
CNBS
34.820
+54.57%
+12.293
MSOS
5.800
+54.26%
+2.040
CGC
1.740
+53.98%
+0.610
RYM
23.800
+47.73%
+7.690
TLRY
12.150
+44.13%
+3.720
View More